The Vaccine Formulation Institute (VFI) and Seppic are pleased to announce that they are expanding their partnership to support the large-scale manufacturing and availability of a saponin-containing oil-in-water emulsion adjuvant designed for human prophylactic vaccines.
Read press release here.
Vaccine Formulation Institute (VFI) and Desert King® (DK) have joined forces in a strategic alliance to revolutionize global access to vaccine adjuvants. This collaboration combines VFI’s open access philosophy and expertise in adjuvant formulation with DK’s world-leading sustainable production and purification of immunostimulating Quillaja saponins. Together, VFI and DK offer vaccine developers a licence-free access to a range of cost-effective liposomal and emulsion-based adjuvants incorporating saponins.
Read Press release here
ISIDORe - “Integrated Services for Infectious Disease Outbreak Research”, has been officially launched on 24 February 2022. This 21M€ EU-funded large-scale project assembles an unprecedented One Health-driven, integrated portfolio of cutting-edge research services and resources, dedicated to the study of epidemic-prone diseases including SARS-CoV-2 variants. VFI offers a range of TransNational Access Services on adjuvants and formulation expertise in order to fight epidemic diseases.
For Press release read here
VFI is pleased to announce its continued partnership with VIDO, thanks to a 5M USD award from CEPI (Coalition of Epidemics Preparedness Innovations), to develop new vaccines that are broadly protective against COVID-19 variants and suitable for use in Low- and Middle-Income Countries. This work builds on the development of COVAC-2, VIDO’s subunit vaccine formulated with Sepivac SWE™, an adjuvant co-developed by Seppic and VFI.
Click here to read VIDO press release and CEPI press release
